STRENSIQ
(Asfotase alfa)Phase 3Protein / enzyme
AstraZenecaSTRENSIQ is one of 24 small molecule programs targeting Pediatric. It is currently in Phase 3.
1
Indications
15
Total Trials
2
Active Trials
23
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Pediatric
#DrugCompanyPhaseTrials
1Oxycontin
PProtega
Approved
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Siliq
BBausch Health Americas, Inc.
Approved
Blincyto
AmgenPhase 3
Venclexta
AbbViePhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Fycompa
CCatalyst Biosciences
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypophosphatasia14 trials
Show 11 more trials
Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)
Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 2·NCT02456038·13 enrolled
Regulatory
FDA Approval Timeline[4]
Oct 23, 2015
STRENSIQ
BLA BLA125513
Oct 23, 2015
STRENSIQ
NDA BLA125513
Oct 18, 2016
STRENSIQ
NDA BLA125513
Jan 26, 2018
STRENSIQ
NDA BLA125513
Jun 12, 2020
STRENSIQ
NDA BLA125513
Jul 10, 2024
STRENSIQ
NDA BLA125513
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Asfotase alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company